Your browser doesn't support javascript.
loading
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat, S; Curioni-Fontecedro, A; Dafni, U; Shah, R; O'Brien, M; Pope, A; Fisher, P; Spicer, J; Roy, A; Gilligan, D; Gautschi, O; Nadal, E; Janthur, W D; López Castro, R; García Campelo, R; Rusakiewicz, S; Letovanec, I; Polydoropoulou, V; Roschitzki-Voser, H; Ruepp, B; Gasca-Ruchti, A; Peters, S; Stahel, R A.
Afiliación
  • Popat S; Royal Marsden Hospital Fulham Road, London, UK.
  • Curioni-Fontecedro A; University Hospital Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland.
  • Dafni U; National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece.
  • Shah R; Kent Oncology Centre, Maidstone, UK.
  • O'Brien M; Royal Marsden Hospital Sutton, London, UK.
  • Pope A; Clatterbridge Cancer Centre, Liverpool, UK.
  • Fisher P; Weston Park Hospital, Sheffield, UK.
  • Spicer J; King's College London, Guy's Hospital, London, UK.
  • Roy A; University Hospital Plymouth, Plymouth, UK.
  • Gilligan D; Addenbrooke's Hospital, Cambridge, UK.
  • Gautschi O; University of Bern and Cantonal Hospital Luzern, Luzern Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Swiss Group for Clinical Cancer Research, Switzerland (SAKK), Bern.
  • Nadal E; Catalan Institute of Oncology (ICO), L'Hospitalet, Barcelona, Spain.
  • Janthur WD; Swiss Group for Clinical Cancer Research, Switzerland (SAKK), Bern; Cantonal Hospital Aarau, Aarau, Switzerland.
  • López Castro R; Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • García Campelo R; Hospital Teresa Herrera, La Coruña, Spain.
  • Rusakiewicz S; Centre Hospitalier Universitaire Vaudois CHUV, Centre of Experimental Therapies and Department of Oncology, Lausanne, Switzerland.
  • Letovanec I; Centre Hospitalier Universitaire Vaudois CHUV, Institute of Pathology, Lausanne, Switzerland.
  • Polydoropoulou V; Frontier Science Foundation-Hellas, Athens, Greece.
  • Roschitzki-Voser H; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Ruepp B; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Gasca-Ruchti A; European Thoracic Oncology Platform (ETOP), Bern, Switzerland.
  • Peters S; Centre Hospitalier Universitaire Vaudois, Department of Oncology, Lausanne, Switzerland.
  • Stahel RA; University Hospital Zürich, Department of Medical Oncology and Hematology, Zürich, Switzerland. Electronic address: Rolf.Stahel@etop-eu.org.
Ann Oncol ; 31(12): 1734-1745, 2020 12.
Article en En | MEDLINE | ID: mdl-32976938
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mesotelioma Maligno Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mesotelioma Maligno Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Reino Unido